Skip to main content
SLS logo

SELLAS Life Sciences Group, Inc.

SLSNASDAQHealthcareBiotechnology

$9.98Today:- (-)1Y +429.91%

As of Oct 16, 2026 close

Market cap
$2.15B
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$1.39$15.88
Volume (live)
-
Avg. volume (3M)
6.07M

SELLAS Life Sciences Group (SLS) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), SELLAS Life Sciences Group used $28.39M of cash in operating activities. Free cash flow was −$28.39M. It repurchased $527.00K of its own shares.

SELLAS Life Sciences Group Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for SELLAS Life Sciences Group, Inc. (SLS) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income-26.86-30.88-37.34-41.30-20.70-16.76-19.29-27.67-23.75
Depreciation & Amortization0.000.000.000.465.690.281.703.760.00
Deferred Income Tax0.000.000.00-0.46-0.24-0.02-0.10-1.320.00
Stock Based Compensation1.961.561.391.731.010.580.570.403.17
Change in Working Capital-4.08-6.653.355.64-7.625.59-1.11-10.016.07
Change in Accounts Payable-0.54-2.142.301.21-2.51-0.840.01-7.948.37
Change in Other Working Capital-1.60-2.321.040.78-5.106.43-1.12-2.07-2.30
Other Operating Activities0.600.561.2010.13-4.16-0.090.594.423.53
Net Cash from Operating Activities-28.39-35.40-31.41-23.81-26.02-10.42-17.64-30.42-10.99
Investing Activities
Capital Expenditures0.000.00-5.50-4.500.000.000.000.000.00
Acquisitions0.000.000.000.000.000.000.000.001.81
Sales/Maturities of Investments0.000.000.00-4.500.000.000.000.000.00
Net Cash from Investing Activities0.000.00-5.50-4.500.000.000.000.001.81
Financing Activities
Debt Repayment0.000.000.000.000.000.000.00-7.60-0.47
Common Stock Issued86.8246.8222.2324.089.0129.6015.9721.566.01
Common Stock Repurchased-0.53-0.060.000.000.000.000.000.000.00
Dividends Paid0.000.000.000.000.000.000.00-0.49-0.68
Other Financing Activities51.04-0.060.090.093.078.843.609.650.00
Net Cash from Financing Activities86.3046.7622.3224.0812.0738.4419.5723.125.53
Summary
Net Change in Cash57.9111.36-14.60-4.23-13.9528.031.93-7.30-3.64
Cash at Beginning of Period13.992.6317.2321.4635.407.385.4512.755.96
Cash at End of Period71.8913.992.6317.2321.4635.407.385.452.32
Free Cash Flow-28.39-35.40-36.91-23.81-26.02-10.42-17.64-30.42-10.99

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About SELLAS Life Sciences Group Cash Flow

What is SELLAS Life Sciences Group's free cash flow?

SELLAS Life Sciences Group had negative free cash flow of $28.39M in fiscal 2025 (fiscal year ended Dec 31, 2025).

Does SELLAS Life Sciences Group pay dividends or buy back shares?

Yes. In fiscal 2025 SELLAS Life Sciences Group returned $527.00K in share buybacks to shareholders, according to its cash flow statement.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition